Literature DB >> 7602617

Differential expression of neurotensin receptor mRNA in the dopaminergic cell groups of the rat diencephalon and mesencephalon.

A Nicot1, W Rostène, A Bérod.   

Abstract

Several lines of evidence support interactions between neurotensin (NT) and dopaminergic (DAergic) neurons in the brain. In order to obtain further knowledge about the anatomical substrate for such interactions, the distribution of cells expressing the cloned neurotensin receptor (NTR) mRNA was examined in relation to tyrosine hydroxylase (TH) mRNA-expressing cells within different subnuclei of the diencephalon and ventral mesencephalon of the male rat. In situ hybridization was performed on consecutive sections labeled with 33P-labeled oligonucleotide probes. In the hypothalamus, NTR mRNA signals were mostly found in the suprachiasmatic, dorsomedial, dorsal premammillary, and supramammillary nuclei. On the other hand, DAergic cells of the periventricular nucleus of the hypothalamus and dorsal aspect of the arcuate nucleus, revealed by TH in situ hybridization, did not exhibit NTR mRNA even though dense NT binding sites have been previously described in this nuclei. In the zona incerta, TH mRNA-containing cells were concentrated in the medial part, with little overlap with NTR mRNA-expressing cells located mainly in its mediolateral extent. In contrast, the distribution of both markers was superimposable within the different subdivisions of the ventral tegmental area and substantia nigra, as previously suggested, but also in the retrorubral field. These anatomical data further support the NT-dopamine interactions on both mesocorticolimbic and nigrostriatal DAergic systems. Moreover, the results suggest that diencephalic DAergic neurons do not synthesize the cloned NTR mRNA or express it at considerably lower levels than DAergic mesencephalic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7602617     DOI: 10.1002/jnr.490400512

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

2.  Correlative ultrastructural distribution of neurotensin receptor proteins and binding sites in the rat substantia nigra.

Authors:  H Boudin; D Pélaprat; W Rostène; V M Pickel; A Beaudet
Journal:  J Neurosci       Date:  1998-10-15       Impact factor: 6.167

3.  Differential binding profile and internalization process of neurotensin via neuronal and glial receptors.

Authors:  D Nouel; M P Faure; J A St Pierre; R Alonso; R Quirion; A Beaudet
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

4.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

5.  Neurotensin inhibits both dopamine- and GABA-mediated inhibition of ventral tegmental area dopamine neurons.

Authors:  Katherine Stuhrman; Aaron G Roseberry
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

6.  Maternal deprivation effect on the infant's neural stress markers is reversed by tactile stimulation and feeding but not by suppressing corticosterone.

Authors:  H J van Oers; E R de Kloet; T Whelan; S Levine
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

7.  Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons.

Authors:  Fannie St-Gelais; Mark Legault; Marie-Josée Bourque; Pierre-Paul Rompré; Louis-Eric Trudeau
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

8.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.